Meds like Wegovy are all over the news. But are they right for you, especially if you’re older than the average user?

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

The demand for weight loss drugs, like Ozempic and Wegovy, has skyrocketed in the past few years despite the high cost and unpleasant side effects for some people. The New York Times reports some patients are finding a way around both of these concerns by experimenting with microdosing the drugs.

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% of their body weight. But the drugs don’t work for everyone. In tho

Prescriptions for weight-loss drugs surged in 2024 and were much more popular in some states, particularly those in the South with higher rates of obesity.

Results from a recent survey have prompted questions about the influence of GLP-1s on the obesity rate of U.S. adults.

In addition, the decline in overall obesity rate reported by the CDC isn’t the first such drop. Between 1999 and 2018, the NHANES results found two instances of slight decreases in obesity rates and two dips in severe obesity rates. These falls were followed by steady increases in both categories.

As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according to cybersecurity experts.